Tevogen (TVGN) Gains from Investment Securities (2022 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Gains from Investment Securities came in at -$25831.0 in Q1 2026, down 86.41% YoY from -$190090.4 in Q1 2025, and down 683.95% on a QoQ basis from -$3295.0 in Q4 2025.
Tevogen (TVGN) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 5 years of Gains from Investment Securities data on file, last reported at -$25831.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 86.41% year-over-year to -$25831.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$72675.0 (down 688.46% YoY) and the FY2025 annual result came in at -$60701.0, down 204.33% from the prior year.
- Gains from Investment Securities retreated to -$25831.0 in Q1 2026, from -$3295.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $72608.0 in Q4 2024 to a low of -$137750.0 in Q2 2022.
- A 5-year average of -$24697.2 and a median of -$13857.0 in 2025 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities surged 1101.49% — and 2025, when it plunged 753.26%.
- Tracing TVGN's Gains from Investment Securities over 5 years: stood at -$87000.0 in 2022, then surged by 91.67% to -$7250.0 in 2023, then surged by 1101.49% to $72608.0 in 2024, then tumbled by 104.54% to -$3295.0 in 2025, then slumped by 683.95% to -$25831.0 in 2026.
- The last three Gains from Investment Securities figures came in at -$25831.0 (Q1 2026), -$3295.0 (Q4 2025), and -$64959.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25,831.00 |
| Mar 31, 2026 | -25,831.00 |
| Dec 31, 2025 | -3,295.00 |
| Dec 31, 2025 | -3,295.00 |
| Sep 30, 2025 | -64,959.00 |
| Sep 30, 2025 | -64,959.00 |
| Jun 30, 2025 | 21,410.00 |
| Jun 30, 2025 | 21,410.00 |
| Mar 31, 2025 | -13,857.00 |
| Mar 31, 2025 | -13,857.00 |
| Dec 31, 2024 | 72,608.00 |
| Dec 31, 2024 | 72,608.00 |
| Sep 30, 2024 | -7,613.00 |
| Sep 30, 2024 | -7,613.00 |
| Jun 30, 2024 | -38,788.00 |
| Jun 30, 2024 | -38,788.00 |
| Mar 31, 2024 | 31,973.00 |
| Mar 31, 2024 | 31,973.00 |
| Dec 31, 2023 | -7,250.00 |
| Dec 31, 2023 | -7,250.00 |